Buscar
Mostrando ítems 31-40 de 859
Functional evolution of the Colony Stimulating Factor 1 Receptor (CSF1R) and its ligands in birds
(Journal of Leukocyte Biology, 2020)
A randomized, multicenter study of G-CSF starting on day+1 vs day+5 after autologous peripheral blood progenitor cell transplantation
(Nature Publishing GroupLondonInglaterra, 2002)
Expression of recombinant human mutant granulocyte colony stimulating factor (Nartograstim) in Escherichia coli
(SPRINGERNEW YORK, 2012)
The human granulocyte colony stimulating factor (hG-CSF) plays an important role in hematopoietic cell proliferation/differentiation and has been widely used as a therapeutic agent for treating neutropenias. Nartograstim ...
The Antiapoptotic Effect of Granulocyte Colony-stimulating Factor Reduces Infarct Size and Prevents Heart Failure Development in Rats
(KARGER, 2011)
Background/Aim. Granulocyte colony-stimulating factor (G-CSF) reduces myocardial injury and improves cardiac function after myocardial infarction (MI). We investigated the early alterations provided by G-CSF and the chronic ...
O G-CSF na terapia do acidente vascular cerebral
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea, 2009)
O fator estimulador de colônias granulocitárias (G-CSF) é uma glicoproteína descrita há mais de vinte anos, e é largamente utilizada para tratamento de estados neutropênicos e no transplante de medula óssea. O G-CSF estimula ...
Human granulocyte colony stimulating factor (hG-CSF): cloning, overexpression, purification and characterization
(Biomed Central Ltd., 2008-04-04)
Background: Biopharmaceutical drugs are mainly recombinant proteins produced by biotechnological tools. The patents of many biopharmaceuticals have expired, and biosimilars are thus currently being developed. Human granulocyte ...
Human granulocyte colony stimulating factor (hG-CSF): cloning, overexpression, purification and characterization
(Biomed Central Ltd., 2008-04-04)
Background: Biopharmaceutical drugs are mainly recombinant proteins produced by biotechnological tools. The patents of many biopharmaceuticals have expired, and biosimilars are thus currently being developed. Human granulocyte ...